Mansfield C, Gebben D, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, Shah N. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019 Mar;59(5):715-26. doi: 10.1111/head.13498
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cerebrovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, Shah N. Patient satisfaction with prophylactic migraine medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 2017. Boston, MA. [abstract] Headache. 2017 Jun; 57(Suppl S3):133.
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
Fehnel SE, Coon CD, Davis KH, Runken MC, Cady RK. Development and Psychometric Evaluation of the Migraine Completeness of Response Survey (CORS). Poster presented at the 52nd Annual Scientific Meeting of the American Headache Society; June 2010. [abstract] Headache. 2010 Aug; 50(s1):S49-50.
Mosconi M, Nelson LM, Hooper SR. Confirmatory Factor Analysis of the NEPSY for younger and older school-age children. Psychol Rep. 2008 Jun;102(3):861-6.
Hartmaier SL, Demuro-Mercon C, Linder S, Winner P, Santanello NC. Development of a brief 24-hour adolescent migraine functioning questionnaire. Headache. 2001 Feb 1;41(2):150-6.